? HIV CURE SWG The HIV Cure Scientific Working Group is designed to provide a platform for generating new research in the area of HIV cure and also to create an environment to mentor and support young investigators. UNC has become an important center of cure research, hosting one of the Delaney Collaboratories, a multi-institution effort that includes Merck Pharmaceutical investigators. In addition the HIV Cure Center was recently formed as a private-public partnership with GSK. UNC also has significant strengths drug discovery, pharmacology, the regulation of chromatin modification, and expanding expertise in HIV immunology looking ahead to therapeutic vaccinations. The first goal of the HIV Cure SWG is to bring together this diverse set of investigators, including collaborators at other CFARs through video conferencing and from industry, to share data and explore ideas for new research pathways. The second goal of the HIV Cure SWG is to mentor and support new investigators on their path to independence. Taken together these two goals will advance cure research in the present and prepare the next generation of cure researchers for their own successes in the future. The HIV Cure SWG will be led by Dr. David Margolis, who also leads the Delaney Care Collaboratory and the HIV Cure Center, and by Dr. Andrew Spaltenstein, who is Vice President of the HIV Discovery Performance Unit of GSK and a new member of the HIV Cure Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-21
Application #
9532774
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
21
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Evon, Donna M; Stewart, Paul W; Amador, Jipcy et al. (2018) A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One 13:e0196908
Gausi, Blessings; Chagomerana, Maganizo B; Tang, Jennifer H et al. (2018) Human Immunodeficiency Virus Serodiscordance and Dual Contraceptive Method Use Among Human Immunodeficiency Virus-infected Men and Women in Lilongwe, Malawi. Sex Transm Dis 45:747-753
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Cheng, Weibin; Xu, Huifang; Zhong, Fei et al. (2018) Can HIV service data be used for surveillance purposes?: a case study in Guangzhou, China. BMC Public Health 18:1268
Gradissimo, Ana; Lam, Jessica; Attonito, John D et al. (2018) Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Biomarkers Prev 27:1407-1415
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Price, Joan T; Mollan, Katie R; Fuseini, Nurain M et al. (2018) Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol. Pilot Feasibility Stud 4:21
Davy-Mendez, Thibaut; Napravnik, Sonia; Zakharova, Oksana et al. (2018) Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr 79:510-518
Cole, Stephen R; Edwards, Jessie K; Westreich, Daniel et al. (2018) Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. Biom J 60:100-114

Showing the most recent 10 out of 1688 publications